A laser spectrometer based on difference frequency generation (DFG) was deployed for real-time long-term monitoring of HCHO concentrations at an environmental monitoring site located at Deer Park, Texas, in the Greater Houston area. Three HCHO concentration measurements were made during the periods of July 20-31 (period I), August 2-14 (period II), and August 24-September 25 (period III), 2002. In periods I and II, differences in HCHO concentrations are apparent between day and night measurements, with elevated concentrations during daylight hours. Most of the HCHO peak values are less than 20 ppbV except for two intense peaks on August 02 (approximately 25 ppbV) and August 04 (approximately 30 ppbV). The formaldehyde concentration levels in ambient air at the measurement site are produced mainly by the photochemical oxidation of volatile organic compounds (VOCs) caused by intense sunlight during periods I and II. This observation was made based on a comparison with the ozone concentration, solar radiation, temperature, relative humidity, and wind speed data obtained from the Texas Commission on Environmental Quality (TCEQ). During period III, data collected by a time-integrating wet-chemical technique are compared to the data collected by the spectroscopic instrument.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1366/000370204322843002 | DOI Listing |
Eur Heart J
January 2025
School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 2199 Lishui Rd, Nanshan, Shenzhen, Guangdong Province 518055, China.
Background And Aims: Lackluster results from recently completed gene therapy clinical trials of VEGF-A delivered by viral vectors have heightened the need to develop alternative delivery strategies. This study aims to demonstrate the pre-clinical efficacy and safety of extracellular vesicles (EVs) loaded with VEGF-A mRNA for the treatment of ischaemic vascular disease.
Methods: After encapsulation of full-length VEGF-A mRNA into fibroblast-derived EVs via cellular nanoporation (CNP), collected VEGF-A EVs were delivered into mouse models of ischaemic injury.
Cancer Med
January 2025
Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Background: Neutrophils interact with tumor cells, potentially exacerbating cancer progression. Additionally, decreased albumin levels are a marker of poor cancer prognosis. The neutrophil-percentage-to-albumin ratio (NPAR) has been used for prognostic assessment in non-cancerous diseases, but its relationship with mortality risk in cancer patients has not been explored.
View Article and Find Full Text PDFPain Pract
February 2025
Department of Anesthesiology, University of Wisconsin, Madison, Wisconsin, USA.
Objective: To compare the efficacy of closed-loop spinal cord stimulation (CL-SCS) and dorsal root ganglion (DRG) stimulation in managing chronic cancer-related pain.
Material/methods: A retrospective review was conducted with IRB exemption for four patients with cancer-related pain who underwent combination stimulator trials. Patients were trialed with both CL-SCS and DRG stimulation for 8-10 days, with assessments of pain relief, functional improvement, sleep improvement, pain medication changes, and overall satisfaction.
Neurol Clin Pract
April 2025
Neurology, Vanderbilt University Medical Center, Nashville, TN.
Background: Huntington disease (HD) is a genetic neurodegenerative disorder. Given the focus on motor manifestations, nonmotor symptoms are frequently underappreciated in clinical evaluations, despite frequently contributing to primary functional impairment.
Recent Findings: A diagnosis of motor-onset as the definition of manifest symptoms misrepresents the complex nature of HD presentation.
Brain Behav Immun
January 2025
Univ Paris Est Créteil, INSERM U955, IMRB, Translational NeuroPsychiatry Laboratory, Fondation FondaMental, Créteil, France. Electronic address:
Despite tremendous advancements in neuroscience, there has been limited impact on patient care. Current psychiatric treatments are largely non-specific, and drug development is hindered by outdated, overinclusive diagnostic categories and a "one-size-fits-all" approach. Additionally, mechanisms underlying psychiatric illnesses and their treatments with conventional medications remain poorly understood.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!